ID
TEVA icon

Integral Derivatives’s Teva Pharmaceuticals TEVA Stock Holding History

Integral Derivatives’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$458K Sell
26,800
-44,100
-62% -$861K 0.01% 406
2017
Q4 		$1.34M Sell
70,900
-1,000
-1% -$15K 0.03% 397
2017
Q3 		$1.26M Buy
71,900
+51,500
+252% +$1.16M 0.02% 418
2017
Q2 		$678K Sell
20,400
-31,200
-60% -$966K 0.01% 608
2017
Q1 		$1.66M Sell
51,600
-71,300
-58% -$2.43M 0.03% 360
2016
Q4 		$4.46M Buy
122,900
+74,400
+153% +$2.97M 0.08% 159
2016
Q3 		$2.23M Buy
48,500
+17,500
+56% +$913K 0.05% 242
2016
Q2 		$1.56M Buy
31,000
+20,200
+187% +$1.08M 0.04% 293
2016
Q1 		$578K Buy
10,800
+5,800
+116% +$340K 0.02% 495
2015
Q4 		$328K Sell
5,000
-1,800
-26% -$111K 0.01% 781
2015
Q3 		$384K Buy
+6,800
New +$441K 0.01% 788
2015
Q2 		– Sell
-9,100
Closed -$567K – 1252
2015
Q1 		$567K Sell
9,100
-24,300
-73% -$1.41M 0.01% 668
2014
Q4 		$1.92M Buy
33,400
+12,300
+58% +$685K 0.03% 449
2014
Q3 		$1.13M Sell
21,100
-25,400
-55% -$1.35M 0.02% 654
2014
Q2 		$2.44M Buy
46,500
+27,500
+145% +$1.41M 0.04% 344
2014
Q1 		$1M Sell
19,000
-17,600
-48% -$813K 0.02% 655
2013
Q4 		$1.47M Buy
+36,600
New +$1.44M 0.02% 627

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Integral Derivatives's TEVA Position: Q2 2017 in Review

Integral Derivatives sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 32,601 shares — an estimated $1.01M sold.

Integral Derivatives first reported a position in TEVA in Q4 2013 and held it in 8 quarters. The position peaked at $2.54M in Q4 2016. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • Integral Derivatives reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Integral Derivatives sold 32,601 Teva Pharmaceuticals shares in Q2 2017, an estimated $1.01M.
  • Integral Derivatives first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 8 quarters.
  • Integral Derivatives's Teva Pharmaceuticals position peaked at $2.54M in Q4 2016.
  • 648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Integral Derivatives's 13F filing for Q2 2017, filed 14 Aug 2017.